Press Releases

Filter Releases
 
Press Releases
Date Title and Summary View
Apr 18, 2018
- ATLAS data demonstrate in silico methods miss most empirically confirmed neoantigens - - ATLAS able to identify inhibitory neoantigens - - Mouse ATLAS melanoma model developed to study mechanism of inhibitory antigens - CAMBRIDGE, Mass., April 18, 2018 (GLOBE NEWSWIRE) --  Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical compan...
Apr 9, 2018
CAMBRIDGE, Mass., April 09, 2018 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing neoantigen cancer vaccines, today announced upcoming presentations at the 2018 Annual Meeting of the American Association for Cancer Research (AACR 2018), taking place April 14-18, 2018 in Chicago, IL. Poster 1...
Mar 12, 2018
CAMBRIDGE, Mass., March 12, 2018 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing neoantigen cancer vaccines, today announced the appointment of Narinder Singh as senior vice president of pharmaceutical sciences and manufacturing. Mr. Singh will be responsible for overseeing Genocea's manufacturi...
Mar 5, 2018
CAMBRIDGE, Mass., March 05, 2018 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing neoantigen cancer vaccines, today announced that Chip Clark, president and chief executive officer, will present a corporate overview at two upcoming investor conferences: Cowen and Company 38th Annual Health...
Feb 15, 2018
- GEN-009 neoantigen vaccine advancing to IND filing - - Balance sheet strengthened with $55m gross proceeds from January equity financing - - Conference call today at 9 am ET - CAMBRIDGE, Mass., Feb. 15, 2018 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing neoantigen cancer vaccines, today...
Feb 12, 2018
CAMBRIDGE, Mass., Feb. 12, 2018 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing neoantigen cancer vaccines, today announced that Ali Behbahani, M.D., a partner in the healthcare group at New Enterprise Associates ("NEA"), has joined its board of directors. NEA was a lead investor in Genocea's $5...
Feb 8, 2018
CAMBRIDGE, Mass., Feb. 08, 2018 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing neoantigen cancer vaccines, today announced that it will host a conference call and live audio webcast on Thursday, February 15, 2018 at 9:00 a.m. ET to discuss financial results for the fourth quarter and year end 2...
Jan 17, 2018
New Enterprise Associates ("NEA") and Vivo Capital significant investors in financing Genocea intends to elect an NEA representative to Genocea board of directors CAMBRIDGE, Mass., Jan. 17, 2018 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company that discovers and develops novel cancer vaccines, announc...
Jan 16, 2018
CAMBRIDGE, Mass., Jan. 16, 2018 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company that discovers and develops novel cancer vaccines, announced today that it intends to offer and sell in concurrent underwritten public offerings (i) shares of its common stock and Class A warrants to purchase shares of common s...
Nov 21, 2017
CAMBRIDGE, Mass., Nov. 21, 2017 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing neoantigen cancer vaccines, today announced that Chip Clark, president and chief executive officer, will participate in a fireside chat at the 29th Annual Piper Jaffray Healthcare Conference on Tuesday, November 28, ...
Nov 8, 2017
CAMBRIDGE, Mass., Nov. 08, 2017 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing neoantigen cancer vaccines, today announced that Chip Clark, president and chief executive officer, will present a company overview at the Stifel 2017 Healthcare Conference on Wednesday, November 15, 2017 at 8:45 a.m...
Nov 7, 2017
- ATLAS continues to demonstrate superiority to in silico methods of neoantigen identification in multiple tumor types - - ATLAS also identifies unique tumor-associated antigen response signatures in patients with lung and colorectal cancers - CAMBRIDGE, Mass., Nov. 07, 2017 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ:GNCA), a bi...
Nov 2, 2017
- SITC presentation to highlight ATLAS™ ability in neoantigen selection - - IND filing for neoantigen cancer vaccine, GEN-009, expected in Q1 2018 - - Conference call today at 9 am ET - CAMBRIDGE, Mass., Nov. 02, 2017 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing neoantigen cancer v...
Oct 26, 2017
CAMBRIDGE, Mass., Oct. 26, 2017 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing neoantigen cancer vaccines, today announced that it will host a conference call and live audio webcast on Thursday, November 2, 2017 at 9:00 a.m. ET to discuss financial results for the third quarter of 2017. Genocea...
Sep 25, 2017
- Superior ATLASTM platform for neoantigen selection (1) - - Exploring strategic alternatives for GEN-003 -- Announces corporate restructuring - CAMBRIDGE, Mass., Sept. 25, 2017 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company discovering and developing novel vaccines and immunotherapies targeting T ce...
Page:
...
Next Last
 
= add release to Briefcase